Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis
In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting.
Authors
- Mads Kirchheiner Rasmussen (ORCID: https://orcid.org/0000-0001-8242-9377)
- C. Schwarz (ORCID: https://orcid.org/0000-0002-2255-398X)
- Lars Iversen (ORCID: https://orcid.org/0000-0003-1816-4508)
- C. Nissen (ORCID: https://orcid.org/0000-0002-5961-9399)
- Lars Erik Bryld (ORCID: https://orcid.org/0000-0003-0016-6791)
- Trine Bertelsen (ORCID: https://orcid.org/0000-0002-4777-1991)
- Kawa Khaled Ajgeiy
- Nikolai Loft (ORCID: https://orcid.org/0000-0002-2950-3280)
- Kasper Fjellhaugen Hjuler (ORCID: https://orcid.org/0000-0001-6082-5096)
- Lone Skov
- Tomas Norman Dam
Institutions
- University of Copenhagen (DK)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Bispebjerg Hospital (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
- Zealand University Hospital (DK)
- Sjællands Universitetshospital, Nykøbing F. (DK)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1001/jamadermatol.2025.5205
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00